-
July 13, 2022
ASCO 2022 Lymphoma In-Depth Bookmark
George Lundberg, MDPresented by Cancer Therapy Advisor, this collection of stories covers new developments in lymphoma treatment that were presented at the 2022 annual meeting of the American Society of Clinical Oncology.
.
-
July 1, 2022
Lymphoma: New Diagnosis and Current Treatment Strategies Bookmark
George Lundberg, MDRead about personalized and targeted treatments for many types of lymphoma in this scientific review paper written for medical and research professionals and published in the Journal of Clinical Medicine.
.
.
-
July 1, 2022
Early Study Finds New Lymphoma Drug Effective Bookmark
George Lundberg, MDAccording to this Newswise press release from Michigan Medicine – University of Michigan, the U.S. Food and Drug Administration (FDA) has approved the drug zanubrutinib to treat marginal zone lymphoma in some patients, based in part on results from a clinical trial led by researchers at University of Michigan Medical School that demonstrated an 80% response rate.
.
-
June 14, 2022
How an Expert Would Manage His Own Advanced Prostate Cancer
With: Marc B. Garnick, MDWhen facing a new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks Marc B. Garnick, MD, how he would handle his own advanced prostate cancer. Dr. Garnick is the Gorman Brothers Professor of Medicine at Harvard Medical School (HMS) and Beth Israel Deaconess Medical Center in Boston, MA. He is also… Read more »
-
June 13, 2022
‘Unprecedented’ 100% of First 14 Untreated Patients With Rectal Cancer Respond to PD-1 Blocker Dostarlimab-gxly Bookmark
George Lundberg, MDIn a remarkable new study, covered in this article from The ASCO Post, 100% of 14 previously untreated patients with mismatch repair-deficient rectal cancer had complete responses—that is, no more signs of their cancer—after treatment with the checkpoint-inhibitor drug dostarlimab (brand name Jemperli) in a phase 2 clinical trial.
.
-
June 13, 2022
Colon Cancer Treatment & Management Bookmark
George Lundberg, MDWritten for physicians and healthcare professionals, Medscape provides this trustworthy, encyclopedic resource for treating and managing metastatic colorectal cancer.
.
-
June 13, 2022
Latest Evidence on Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer: A 2022 Update Bookmark
George Lundberg, MD
This scientific research paper from Critical Reviews in Oncology/Hematology discusses current options for treatments known as immune checkpoint inhibitors for people with advanced colorectal cancer..
-
June 10, 2022
Emerging Treatment Options for Advanced or Recurrent Endometrial Cancer Bookmark
George Lundberg, MDThis 2022 scientific review article from the Journal of the Advanced Practitioner in Oncology discusses new treatment options for people with advanced endometrial cancer.
.
-
June 10, 2022
NCI Overview of Uterine Cancer Bookmark
George Lundberg, MDThe National Cancer Institute provides this online overview of uterine cancer that is up-to date, comprehensive, and written specifically for patients.
.
-
June 10, 2022
NCCN Guidelines for Patients: Endometrial Cancer Bookmark
George Lundberg, MDEndometrial cancer is the most common kind of uterine cancer. The nonprofit National Comprehensive Cancer Network (NCCN) publishes guidelines for patients to learn more about their diagnosis and their treatment options. Here is their most recent guideline for people with endometrial cancer.
.
Treatment Options
Learn about the latest treatments for advanced cancer. We’ve got it covered, from new FDA approvals to emerging approaches in immunotherapy, targeted therapy, cancer vaccines, modified viruses, and more.
